Repository hosted by TU Delft Library

Home · Contact · About · Disclaimer ·
 

Lung damage in the rat after irradiation and treatment with cytotoxic drugs

Author: Varekamp, A.E. · Vries, A.J. de · Hagenbeek, A.
Type:article
Date:1986
Institution: Radiobiologisch Instituut TNO
Source:British Journal of Cancer, SUPPL. 7, 53, 347-350
Identifier: 230214
Keywords: cyclophosphamide · cytarabine · cytotoxic agent · animal experiment · animal model · drug cytotoxicity · drug efficacy · histology · interstitial pneumonia · intoxication · intraperitoneal drug administration · intravenous drug administration · irradiation · lung function · lung injury · methodology · nonhuman · radiation injury · respiratory system · breathing · drug effect · LD 50 · pathophysiology · radiation exposure · radiation response · rat strain · Animal · Cyclophosphamide · Cytarabine · Dose-Response Relationship, Drug · Dose-Response Relationship, Radiation · Female · Lethal Dose 50 · Lung · Rats · Rats, Inbred Strains · Respiration

Abstract

Interstitial pneumonitis (IP) is one of the major complications after allogeneic bone marrow transplantation (incidence: 30 to 50%, fatality rate: 50 to 60%). Cytomegalovirus is associated with 60% of the cases. When no infectious agent can be detected, it is classified as idiopathic IP (IIP). Factors related to IIP are: remission induction chemotherapy, pretransplant conditioning regimen - usually including total body irradiation and cyclophosphamide (CY) - Graft-versus-Host disease and posttransplant immunosuppression. The influence on the lung by these various factors, separately and in combination, is presently being investigated in a rat model. Consecutive studies have been focussed on lung injury by radiation, CY and cytosine arabinoside (Ara-C). Parameters for evaluation of lung damage were lung function measurements, animal survival (LD50-180) and histopathology. Detailed histological examination will be dealt with elsewhere. Chemicals/CAS: cyclophosphamide, 50-18-0; cytarabine, 147-94-4, 69-74-9; Cyclophosphamide, 50-18-0; Cytarabine, 147-94-4